August Troendle Sells 3,728 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 3,728 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $600.85, for a total transaction of $2,239,968.80. Following the sale, the chief executive officer directly owned 642,456 shares of the company’s stock, valued at $386,019,687.60. The trade was a 0.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Medpace Stock Performance

MEDP opened at $578.30 on Friday. The company has a market capitalization of $16.14 billion, a P/E ratio of 33.90, a PEG ratio of 2.61 and a beta of 1.15. The company has a 50-day moving average of $504.72 and a 200-day moving average of $493.19. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same period last year, the business posted $3.10 earnings per share. The firm’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Medpace

Institutional investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC increased its position in shares of Medpace by 164.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 3,653 shares of the company’s stock worth $2,086,000 after acquiring an additional 2,274 shares in the last quarter. Cerity Partners LLC lifted its position in shares of Medpace by 41.0% in the 4th quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock valued at $45,478,000 after acquiring an additional 23,530 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of Medpace by 24,930.4% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 101,373 shares of the company’s stock valued at $56,936,000 after acquiring an additional 100,968 shares in the last quarter. UBS Group AG boosted its stake in Medpace by 32.8% in the 4th quarter. UBS Group AG now owns 328,879 shares of the company’s stock worth $184,715,000 after purchasing an additional 81,250 shares during the period. Finally, Mitchell Capital Management Co. acquired a new position in Medpace in the 4th quarter worth approximately $3,383,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on MEDP. Barclays set a $600.00 target price on Medpace in a research report on Thursday, July 23rd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Mizuho increased their price target on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Finally, Leerink Partners set a $620.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Two investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.